{"id":"NCT00942604","sponsor":"Peplin","briefTitle":"A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","officialTitle":"A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.05%, In Patients With Actinic Keratoses on Non-head Locations (REGION-Ib)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2009-07-21","resultsPosted":"2012-03-19","lastUpdate":"2015-03-06"},"enrollment":203,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratoses"],"interventions":[{"type":"DRUG","name":"PEP005 (ingenol mebutate) Gel","otherNames":[]},{"type":"DRUG","name":"Vehicle gel","otherNames":[]}],"arms":[{"label":"PEP005 (ingenol mebutate) Gel","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.","primaryOutcome":{"measure":"Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions","timeFrame":"57 days","effectByArm":[{"arm":"PEP005 (Ingenol Mebutate) Gel","deltaMin":42,"sd":null},{"arm":"Vehicle Gel","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":17,"countries":["United States"]},"refs":{"pmids":["22417254"],"seeAlso":["http://www.fda.gov/"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":100},"commonTop":["Application site pruritus","Application site irritation"]}}